Vertex 2nd-qtr results beat expectations

31 July 2020

Shares of Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) rose 1% late yesterday, after it reported consolidated financial results for the second quarter ended June 30, 2020, which exceeded expectations, and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues.

Total product revenues increased 62% to $1.52 billion, compared to the second quarter of 2019, primarily driven by the uptake of Trikafta in the USA and the uptake of Vertex’ medicines outside the USA following the completion of key reimbursement agreements in 2019, and beating analysts’ forecasts of $1.39 billion.

Vertex earnings per share, on an adjusted basis, more than doubled from the year-earlier quarter to $2.61 per share. Analysts polled by FactSet had projected $2.06.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK